Short-term application of telmisartan combined with high-dose atorvastatin in the treatment of coronary heart disease associated with paroxysmal atrial fibrillation
WU Zhe-bing;Dept. of Cardiology,the First People's Hospital of Pingdingshan City;
Objective To explore the clinical efficacy and safety of the short-term application of telmisartan combined with high dose atorvastatin for the treatment of coronary heart disease associated with paroxysmal atrial fibrillation(PAF). Methods The 120 cases by the dynamic electrocardiogram(ECG) or onset's ECG confirmed as coronary heart disease associated with paroxysmal atrial fibrillation were randomly divided into control group,telmisartan group and combination group;the three groups of patients were given standard drug therapy for their coronary heart disease. The timissartan group was combined with timissartan,and the combined treatment group was given 60 mg atorvastatin per day on the basis of timissartan. Three groups of patients before treatment and after treatment received inspection respectively 90 d by the specialist with cardiac color Doppler for examination of left atrial Max. diameter,and with dynamic electrocardiogram to know atrial fibrillation happen at the same time,on an empty stomach per 30 d their blood lipid,renal function,liver function index were detected,cardiovascular events were recorded,and compared above data before and after treatment between three groups.Results 1)In control group,and telmisartan group left atrial diameter index after treatment was significantly decreased,but there was no statistically difference than before treatment(P 0.05);combination treatment group before and after the treatment left atrial diameter value index decreased significantly,the difference was statistically significant(P0.05). 2)The incidence of primary atrial fibrillation before and after treatment group was significantly lower than that in control group,and the difference was statistically significant(P0.05). 3)The blood lipid,liver function,renal function and incidence of cardiovascular events in combination treatment group had no significant difference(P 0.05) than control group. Conclusion Atorvastatin,besides its regulacting lipid effect,short-term applications of its high-dose can also improve the coronary heart disease associated with paroxysmal atrial fibrillation patient's left atrial structure and prognosis,and combined with telmisartan can significantly reduce the frequency of paroxysmal atrial fibrillation,so short-term application of it is safe,can uplift exercise tolerance,improve clinical symptoms,worth for clinical promotion.
【CateGory Index】： R541.4;R541.75